Antibody-drug conjugates (ADCs) are typically composed of a monoclonal antibody (mAbs) covalently bonded to a biologically active cytotoxic drug via a chemical linker. The mAb can then bind to a specific target protein or receptor, allowing the delivery of the drug into the target cell.
This combination allows for a highly specific targeting and potent killing effect to achieve accurate and efficient elimination of target cells, without harming healthy cells. This is particularly desirable in treating cancer, as chemotherapy has poor specificity towards tumor tissues and has toxicities to healthy tissues.1
Although most developed ADCs are designed to treat cancer, ongoing research are attempting to use ADCs to treat different diseases such as atherosclerosis, bacteremia, and inflammatory diseases. Furthermore, development of bispecific ADCs, as well as combinations of ADCs with immunotherapy, are anticipated to produce more safe and efficacious therapies.2
At Biointron, we are dedicated to accelerating antibody discovery for the development of antibody-based drugs for various diseases. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Pettinato, M. C. (2021). Introduction to Antibody-Drug Conjugates. Antibodies, 10(4). https://doi.org/10.3390/antib10040042
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy, 7(1), 1-25. https://doi.org/10.1038/s41392-022-00947-7
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
